Literature DB >> 34244160

Impact of Race, Ethnicity, and Socioeconomic Status over Time on the Long-term Survival of Adolescent and Young Adult Hodgkin Lymphoma Survivors.

Amy M Berkman1, Clark R Andersen2, Vidya Puthenpura3, J Andrew Livingston4, Sairah Ahmed5, Branko Cuglievan6, Michelle A T Hildebrandt5, Michael E Roth7.   

Abstract

BACKGROUND: Although there are growing numbers of adolescent and young adult (AYA) Hodgkin lymphoma (HL) survivors, long-term overall survival (OS) patterns and disparities in this population are underreported. The aim of the current study was to assess the impact of race/ethnicity, socioeconomic status (SES), rurality, diagnosis age, sex, and HL stage over time on long-term survival in AYA HL survivors.
METHODS: The authors used the Surveillance, Epidemiology, and End Results (SEER) registry to identify survivors of HL diagnosed as AYAs (ages 15-39 years) between the years 1980 and 2009 and who were alive 5 years after diagnosis. An accelerated failure time model was used to estimate survival over time and compare survival between groups.
RESULTS: There were 15,899 5-year survivors of AYA HL identified, with a median follow-up of 14.4 years and range up to 33.9 years from diagnosis. Non-Hispanic black survivors had inferior survival compared with non-Hispanic white survivors [survival time ratio (STR): 0.71, P = 0.002]. Male survivors, older age at diagnosis, those diagnosed at higher stages, and those living in areas of higher SES deprivation had unfavorable long-term survival. There was no evidence of racial or sex-based survival disparities changing over time.
CONCLUSIONS: Racial, SES, and sex-based disparities persist well into survivorship among AYA HL survivors. IMPACT: Disparities in long-term survival among AYA HL survivors show no evidence of improving over time. Studies investigating specific factors associated with survival disparities are needed to identify opportunities for intervention. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34244160      PMCID: PMC8419153          DOI: 10.1158/1055-9965.EPI-21-0103

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  59 in total

1.  Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study.

Authors:  Anthony J Swerdlow; Craig D Higgins; Paul Smith; David Cunningham; Barry W Hancock; Alan Horwich; Peter J Hoskin; T Andrew Lister; John A Radford; Ama Z S Rohatiner; David C Linch
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

2.  The new statistics: why and how.

Authors:  Geoff Cumming
Journal:  Psychol Sci       Date:  2013-11-12

3.  Disparities in Adolescent and Young Adult Sarcoma Survival: Analyses of the Texas Cancer Registry and the National SEER Data.

Authors:  Jaqueline C Avila; J Andrew Livingston; Ana M Rodriguez; Anne C Kirchhoff; Yong-Fang Kuo; Sapna Kaul
Journal:  J Adolesc Young Adult Oncol       Date:  2018-08-10       Impact factor: 2.223

4.  Ethnic, Racial, and Socioeconomic Disparities in Retinoblastoma.

Authors:  Bao Truong; Adam L Green; Paola Friedrich; Karina B Ribeiro; Carlos Rodriguez-Galindo
Journal:  JAMA Pediatr       Date:  2015-12       Impact factor: 16.193

5.  Cancer statistics for adolescents and young adults, 2020.

Authors:  Kimberly D Miller; Miranda Fidler-Benaoudia; Theresa H Keegan; Heather S Hipp; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2020-09-17       Impact factor: 508.702

6.  Cause-Specific Mortality Following Initial Chemotherapy in a Population-Based Cohort of Patients With Classical Hodgkin Lymphoma, 2000-2016.

Authors:  Graça M Dores; Rochelle E Curtis; Nicole H Dalal; Martha S Linet; Lindsay M Morton
Journal:  J Clin Oncol       Date:  2020-09-18       Impact factor: 44.544

7.  Adolescent and young adult oncology-past, present, and future.

Authors:  Allison G Close; Alexandra Dreyzin; Kimberly D Miller; Brittani K N Seynnaeve; Louis B Rapkin
Journal:  CA Cancer J Clin       Date:  2019-10-08       Impact factor: 508.702

Review 8.  Hodgkin lymphoma: A review and update on recent progress.

Authors:  Satish Shanbhag; Richard F Ambinder
Journal:  CA Cancer J Clin       Date:  2017-12-01       Impact factor: 508.702

9.  Conditional relative survival among long-term survivors of adolescent and young adult cancers.

Authors:  Chelsea Anderson; Andrew B Smitherman; Hazel B Nichols
Journal:  Cancer       Date:  2018-05-09       Impact factor: 6.860

10.  Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet       Date:  2018-11-08       Impact factor: 79.321

View more
  4 in total

1.  Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors.

Authors:  Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J A Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth
Journal:  Cancer Epidemiol       Date:  2021-09-28       Impact factor: 2.984

2.  Social Genomics as a Framework for Understanding Health Disparities Among Adolescent and Young Adult Cancer Survivors: A Commentary.

Authors:  Lauren V Ghazal; Steve Cole; John M Salsman; Lynne Wagner; Fenghai Duan; Ilana Gareen; Lauren Lux; Susan K Parsons; Christabel Cheung; David M Loeb; Pinki Prasad; Shira Dinner; Brad Zebrack
Journal:  JCO Precis Oncol       Date:  2022-06

3.  Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis.

Authors:  Amy M Berkman; Clark R Andersen; Branko Cuglievan; David C McCall; Philip J Lupo; Susan K Parsons; Courtney D DiNardo; Nicholas J Short; Nitin Jain; Tapan M Kadia; J A Livingston; Michael E Roth
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-06-01       Impact factor: 4.090

4.  The cancer survival index-A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies.

Authors:  Alexander Gaiger; Simone Lubowitzki; Katharina Krammer; Elisabeth L Zeilinger; Andras Acel; Olivera Cenic; Andrea Schrott; Matthias Unseld; Anahita Paula Rassoulian; Cathrin Skrabs; Peter Valent; Heinz Gisslinger; Christine Marosi; Matthias Preusser; Gerald Prager; Gabriela Kornek; Robert Pirker; Günther G Steger; Rupert Bartsch; Markus Raderer; Ingrid Simonitsch-Klupp; Renate Thalhammer; Christoph Zielinski; Ulrich Jäger
Journal:  Cancer Med       Date:  2022-03-22       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.